
FDA Approves Landmark Pancreatic Cancer Drug That Nearly Doubles Patients’ Survival
The FDA approved a new pancreatic cancer pill this week after trial results showed it nearly doubled patient survival. The Food and Drug Administration signed off on Rasonque, known chemically as daraxonrasib, on Wednesday. The daily pill was developed by…














